Physician profile
Benjamin Morgan
NPI 1861888927
$2,359.92
in general payments reported to CMS, 2019-2025
29 companies · $416 in 2025
The $416 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $219 · 2021: $791 · 2022: $445 · 2023: $321 · 2024: $168 · 2025: $416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $905.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $905.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.67 | 2021-2025 | |
| Novo Nordisk INC | $479.10 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $294.64 | 2021-2024 | Mounjaro, Zepbound |
| Amgen INC. | $157.75 | 2020-2025 | Otezla, Repatha |
| Glaxosmithkline, LLC. | $100.74 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Amarin Pharma, INC. | $78.64 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $64.32 | 2022 | |
| Dexcom, INC. | $55.26 | 2021-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.67 | 2021-2023 | Xifaxan |
| Esperion Therapeutics, INC. | $48.66 | 2021 | |
| Exact Sciences Corporation | $46.71 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Ardelyx, INC. | $42.38 | 2025 | Ibsrela |
| Allergan, INC. | $41.57 | 2020 | |
| Mylan Specialty L.P. | $41.55 | 2021-2023 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $41.23 | 2021 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $38.74 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $32.75 | 2025 | Gvoke Hypopen |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.44 | 2021 | |
| Astellas Pharma US INC | $23.61 | 2020 | |
| Phathom Pharmaceuticals, INC. | $23.42 | 2025 | Voquezna |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $22.97 | 2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $17.49 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.84 | 2022 | |
| Paratek Pharmaceuticals, INC. | $15.35 | 2025 | Nuzyra |
| Viatris Specialty LLC | $14.00 | 2025 | Yupelri |
| Pfizer INC. | $13.21 | 2023 | |
| Sanofi-Aventis U.S. LLC | $13.16 | 2021 | |
| Astrazeneca Pharmaceuticals Lp | $12.90 | 2021 | |
| Eisai INC. | $12.15 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.